Log in to save to my catalogue

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSC...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSC...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11027629

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

About this item

Full title

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Cancer Immunology, Immunotherapy, 2020-11, Vol.69 (11), p.2209-2221

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Background
Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%.
Methods
We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness i...

Alternative Titles

Full title

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11027629

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11027629

Other Identifiers

ISSN

0340-7004

E-ISSN

1432-0851

DOI

10.1007/s00262-020-02613-9

How to access this item